|
Thursday - May 8
|
|
|
|
11.30 - 12.45
|
Satellite lunch symposium - Astra Zeneca - Drama Hall
Balancing efficacy and safety as treatment opportunities are expanding - The importance of multidisciplinary decisions
Chair - Martin Sandelin, MD, PhD, Global Medical Affairs Leader, Lung Cancer, AstraZeneca
|
|
| 13.00 - 13.15 |
Welcome, program overview - Drama Hall
|
Jan Nyman, Sweden |
| 13.15 - 15.00 |
Lung cancer screening - Chair - Mikael Johansson, Sweden
|
|
13.15 - 13.20
|
Introduction
|
Mikael Johansson, Sweden |
| 13.20 - 13.40 |
Lung Cancer Screening worldwide – promises and challenges for the future
|
Hilary Robbins, France |
| 13.40 – 14.00 |
Biomarkers for targeted Lung Cancer Screening
|
Mattias Johansson, France
|
| 14.00 - 14.10 |
Lung Cancer Screening in Norway
|
Haseem Ashraf, Norway |
| 14.10 - 14.20 |
Lung Cancer Screening in Denmark
|
Michael Stenger, Denmark |
| 14.20 - 14.30 |
Lung Cancer Screening in Finland
|
Tytti Sarkela, Finland |
| 14.30 - 14.40 |
Lung Cancer Screening in Sweden
|
Mikael Johansson, Sweden |
| 14.40 - 14.50 |
Discussion and concluding remarks
|
Mikael Johansson, Sweden and panel of all speakers in the session |
| 14.50 - 15.00 |
Incidental Pulmonary Nodules - proposal for a Pan-Nordic guideline for description and follow-up.
|
Torben Riis Rasmussen, Denmark |
| 15.00 - 15.30 |
Coffee break, exhibition and poster viewing
|
|
| |
|
|
| 15.30 - 16.30 |
Lung cancer registers in the Nordic countries - Chair Gunnar Wagenius, Sweden - Drama Hall
|
|
| 15.30 - 15.40 |
The Norwegian lung cancer register
|
Lars Fjellbirkeland, Norway |
| 15.40 - 15.50 |
The Danish lung cancer register
|
Zaigham Saghir, Denmark |
| 15.50 - 16.00 |
The Swedish lung cancer register |
Gunnar Wagenius, Sweden |
| 16.00 - 16.10 |
Register in Finland |
Tytti Särkeala, Finland |
| 16.10 - 16.30 |
Discussion – How can we cooperate?
|
|
| 16.30 - 17.15 |
Small-cell lung cancer: State of the art |
Bjørn-Henning Grønberg, Norway |
| |
|
|
| 17.15-18.30 |
Mingle at the 32nd floor
|
|
| 19.00 - |
Dinner on your own
|
|
| |
|
|
|
Friday - May 9
|
|
|
| 08.30 - 10.00 |
Combined strategies in locally advanced lung cancer - Chair - Andreas Hallqvist, Sweden - Drama Hall
|
|
08.30 - 08.45
|
Introduction and update on chemoradiotherapy
|
Andreas Hallqvist, Sweden
|
| 08.45 - 09.15 |
Neoadjuvant chemoimmunotherapy, literature review and the Finnish experience
|
Eero Sihvo, Finland |
09.15 - 09.45
|
Neoadjuvant chemoimmunotherapy, surgical aspects and the Danish experience
|
René Horsleben Petersen, Denmark |
09.45 - 10.00
|
Pathologic assessment of surgical specimens after neoadjuvant chemoimmunotherapy - Experiences, challenges and implications
|
Maria Ramnefjell, Norway
|
| 10.00 - 10.30 |
Coffee break, exhibition and poster viewing
|
|
| 10.30 - 11.00 |
Pro’s and Con’s discussion |
|
| 10:30 - 10:45 |
Combined strategies in locally advanced lung cancer– Neoadjuvant chemoimmunotherapy should be given to everyone |
Bengt Bergman Sweden
|
| 10:45 - 11:00 |
Combined strategies in locally advanced lung cancer - Neoadjuvant chemoimmunotherapy in rare cases only
|
Mikael Johansson, Sweden |
| 11.00 - 11.45 |
Pleural Mesothelioma - State of the Art - Chair- Lena Olsson, Sweden
|
Jens Benn Sørensen, Denmark |
| 12.00 - 13.00 |
Lunch and exhibition
|
|
|
13.00 - 16.00
|
Breakout sessions
(Coffee break, exhibition and poster viewing ≈ 14.30)
|
|
| 13.00 - 16.00 |
Lung cancer biomarkers - Chair - Maria Planck, Sweden - Drama Hall
|
|
| 13.00 - 13.20 |
Technical and clinical aspects of circulating tumor-DNA analysis in cancer management
|
Anders Ståhlberg,Sweden |
| 13.20 - 13.40 |
Use of ctDNA analyses in lung cancer.
|
Peter Meldgaard, Denmark |
| 13.40 - 14.00 |
National lung cancer pilot - broad sequencing of tissue and ctDNA on the GMS560 platform
|
Johan Botling, Sweden |
| 14.00 - 14.20 |
Circulating tumor DNA guided treatment monitoring in advanced lung cancer - a randomized interventional study
|
Malene Støchkel Frank, Denmark |
| 14.20 - 15.00 |
Coffee break, exhibition and poster viewing |
|
| 15.00 - 16.00 |
Lung cancer biomarkers - Chair - Johan Botling, Sweden - Drama Hall
|
|
| 15.00 - 15.20 |
Aging, metabolism and KRAS-driven lung cancer: Do tumors in the elderly refuse growing up?
|
Volkan Sayin, Sweden |
| 15.20 - 15.40 |
Clinical proteomics for improved precision medicine in lung cancer
|
Lukas Orre, Sweden |
| 15.40 - 16.00 |
A prospective Nordic immune cell study; what has been the most important outcomes – primary aims or building new networks initiating further research?
|
Tom Dønnem, Norway |
| 13.00 - 14.30 |
Stereotactic Body Radiotherapy (SBRT) and beyond - Chair - Jan Nyman, Sweden - The Cutting Room
|
|
| 13.00 - 13.20 |
The HILUS trials; centrally located tumors
|
Karin Lindberg, Sweden |
| 13.20 - 13.40 |
The STRICT and STAR trials and experience with MR-linac
|
Mette Pøhl, Denmark |
| 13.40 - 13.55 |
OLIGO-DK, SOFT and Bony M trials
|
Gitte Persson, Denmark |
| 13.55 - 14.10 |
NORTHDIP: Nordic specialist RT education program
|
Jens Engleson, Sweden |
| 14.10 - 14.25 |
COM-IT-2 trial
|
Vilde Drageset Haakensen, Norway |
| 14.25 - 14.30: |
Wrap up, discussion
|
|
| |
|
|
| 14.30 - 16.30 |
Breakout sessions
|
|
| 14.30 - 16.00 |
Quality of life in lung cancer - Chair - Bengt Bergman, Sweden - The Cutting Room
|
|
| 14.30 - 15.00 |
Web-based symptom monitoring and survival in advanced stage lung cancer
|
Mats Lambe/Elin Backman-Stålnacke, Sweden |
| 15.00 - 15.20 |
Health related quality of life in long-term survivors treated with chemoradiotherapy for locally advanced Non-Small Cell Lung Cancer
|
Kerstin Gunnarsson, Sweden |
| 15.20 - 16.00 |
How long to treat, and when to stop treatment in advanced lung cancer?
|
Bengt Bergman, Sweden |
| 14.30 - 16.30 |
Surgery and endobronchial interventions - Chair - Per Landelius & Maya Landenhed Smith - The Test Screening Room
|
|
| 14.30 - 14.40 |
Introduction
|
Per Landelius & Maya Landenhed Smith, Sweden |
| 14.40 - 15.05 |
Preoperative planning and strategies for minimizing locoregional recurrence after parenchyma sparing surgery for NSCLC
|
René Horsleben Petersen, Denmark |
| 15.05 - 15.30 |
Percutaneous ablation therapy of lung tumours
|
Pär Dahlman, Sweden
|
| 15.30 - 16.00 |
EBUS Mediastinal Cryobiopsy: The next step in mediastinal assessment
|
Ilias Lyroudis, Sweden
|
| 16.00 - 16.25 |
Sleeve resection as a parenchyma sparing technique in the era of neoadjuvant chemoimmuno therapy
|
Fredrik Yannopoulos, Finland
|
| 16.25 - 16.30 |
Closing remarks
|
|
| 15.00 - 16.00 |
AI in lung cancer - Chair - Luigi de Petris, Sweden - The Cinema
|
|
| 15.00 - 15.15 |
AI as a tool in lung cancer screening
|
Nicolas Peyrard Janvid, Sweden |
| 15.15 - 15.30 |
DINASTY in NSCLC - a real world data study using federated analysis
|
Åsa Kristina Öjlert, Norway |
| 15.30 - 15.45 |
AI used in outcome prediction based on imaging in lung cancer
|
Ida Häggström Sweden |
| 15.45 - 16.00 |
AI used in outcome prediction based on clinical data in SCLC
|
Asaf Dan, Sweden |
| 19.00 - |
Conference dinner at Långedrag Värdshus, Talattagatan 24
|
|
| |
|
|
|
Saturday - May 10
|
|
|
|
08.30 - 09.00
|
Satellite breakfast symposium - Accord Healthcare - Drama Hall
News and challenges in small cell lung cancer (SCLC)
Chair - Simon Ekman, Sweden - Drama Hall
|
Francesco Grossi, Italy |
|
09.00 - 10.00
|
Clinical academic studies in the Nordic countries - Chair - Jan Nyman, Sweden - Drama Hall
|
|
|
09.00 - 09.15
|
The Danish experience
|
Tine Skytte, Denmark |
|
09.15 - 09.30
|
The Norwegian experience
|
Tarje Halvorsen, Norway |
|
09.30 - 09.45
|
The Finnish experience
|
Heidi Andresén, Finland |
|
09.45 - 10.00
|
The Swedish experience
|
Jan Nyman, Sweden |
|
10.00 - 10.45
|
Oral presentation of selected abstracts. Awards for best posters- Drama Hall
Chair - Maria Planck, Sweden
|
|
|
10.00 - 10.10
|
Aging promotes lung cancer metastasis through epigenetic induction of integrated stress response
|
Angana Patel, Sweden |
|
10.10 - 10.20
|
Route to diagnosis in Danish Lung Cancer Patients
|
Anja Gouliaev, Denmark |
|
10.20 - 10.30
|
Metastasized lung cancer with EGFR mutation and the TKI inhibitor sequence in a population-based cohort study in Sweden
|
Gudrun Oskarsdottir, Sweden
|
|
10.30 - 10.45
|
Discussion
|
|
|
10.45 - 11.15
|
Coffee break, exhibition and poster viewing
|
|
| 11.15 - 12.30 |
Targeted therapy – treatment and testing - Chair Johan Botling, Sweden
|
|
| 11.15 - 11.40 |
Targeting ALK - molecular mechanisms, next generation TKIs and evolution of treatment paradigms in the ALK-positive tumor landscape"
|
Ruth Palmer, Sweden |
| 11.40 - 11.55 |
How to deal with heterogenous genomic alterations in NSCLC patients with ALK-rearrangements
|
Edyta Urbanska, Denmark |
| 11.55 - 12.10 |
New targeted agents for rare genomic drivers (HER2, EGFR exon 20)
|
Luigi De Petris, Sweden |
| 12.10 - 12.30 |
CNS-progression during targeted therapy
|
Simon Ekman, Sweden |
| 12.30 - 13.30 |
Lunch, exhibition and poster viewing
|
|
| 13.30 - 15.00 |
Targeted therapy – treatment and testing - Chair - Simon Ekman, Sweden
|
|
| 13.30 - 13.50 |
Intrinsic and acquired resistance to EGFR-TKIs: What to look for?
|
Eric Santoni-Rugiu, Denmark |
| 13.50 - 14.10 |
KRAS Crash Course - biology and treatment
|
Johan Botling/Ella Äng, Sweden |
| 14.10 - 14.30 |
Lung cancer in never smokers
|
Maria Planck, Sweden |
| 14.30 - 14.50 |
Use of targeted therapies in neoadjuvant/adjuvant setting - future perspektives.
|
Odd Terje Brustugun, Norway |
